← All trials
NCT05425940
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Jun 21, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ExelixisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.